The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global health concern. The development of vaccines with high immunogenicity and safety is crucial for controlling the global COVID-19 pandemic and preventing further illness and fatalities. Here, we report the development of a SARS-CoV-2 vaccine candidate, Nanocovax, based on recombinant protein production of the extracellular (soluble) portion of the spike (S) protein of SARS-CoV-2. The results showed that Nanocovax induced high levels of S protein-specific IgG and neutralizing antibodies in three animal models: BALB/c mouse, Syrian hamster, and a non-human primate ( Macaca leonina ). In addition, a viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. Nanocovax did not induce any adverse effects in mice ( Mus musculus var. albino) and rats ( Rattus norvegicus ). These preclinical results indicate that Nanocovax is safe and effective.
【저자키워드】 COVID-19, SARS-CoV-2, ACE2, RBD, CHO, 【초록키워드】 coronavirus disease, neutralizing antibody, IgG, Vaccine, coronavirus, pandemic, SARS-COV-2 infection, COVID-19 pandemic, SARS-CoV-2 vaccine, Protein, Health, mice, non-human primate, upper respiratory tract, Safe, viral challenge, adverse effect, acute respiratory syndrome, BALB/c, VAR, effective, Extracellular, caused, addition, induce, Mus, Rattus, 【제목키워드】 Safety, response, Preclinical,